Avenzo Therapeutics, Inc. — Form D/A
Avenzo Therapeutics, Inc. of SAN DIEGO, CA, a company, filed a Form D amendment with the SEC on 2024-03-26. The offering totals $346.9M, of which $223.4M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2024-03-26
- Form: D/A
- Accession: 0001947742-24-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $346.9M
- Amount sold: $223.4M
- Remaining: $123.5M
- Investors: 19
- Date of first sale: 2022-09-14
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-460216
Issuer
- Name: Avenzo Therapeutics, Inc.
- CIK: 0001947742
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2022
- Address: 12707 High Bluff Drive, Suite 200, SAN DIEGO, CA, 92130
- Phone: (858) 239-2944
Officers, directors & promoters (13)
| Name | Role | Location |
|---|
| Michael Rome | Director | Palm Beach, FL |
| CARL GORDON | Director | SAN DIEGO, CA |
| Simeon George | Director | Redwood City, CA |
| Garry Nicholson | Director | San Diego, CA |
| Patrick Machado | Director | San Diego, CA |
| Judith Li | Director | San Diego, CA |
| Paolo Tombesi | Executive Officer | San Diego, CA |
| Mohammad Hirmand | Executive Officer | San Diego, CA |
| Scott Lipman | Executive Officer | San Diego, CA |
| Athena Countouriotis | Director | San Diego, CA |
| Athena Countouriotis | Executive Officer | San Diego, CA |
| Brian Sun | Executive Officer | San Diego, CA |
| Jakob Dupont, M.D., M.A. | Director | San Diego, CA |
Other filings by this issuer (3)
More